Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23
NEW ORLEANS — In back-to-back presentations on Monday with its Phase III data on a drug for pulmonary arterial hypertension, Merck unveiled new mid-stage data on an oral cholesterol-lowering drug for heart disease.
The 381-person Phase II study tested four doses of Merck’s oral PCSK9 inhibitor ranging from 6 mg to 30 mg in patients with high cholesterol. At the lowest dose, patients saw their cholesterol levels fall by 41% over the eight-week treatment period, while patients at the highest dose saw their cholesterol levels fall by 61%. The data were presented at the American College of Cardiology annual meeting and simultaneously published in the Journal of the American College of Cardiology.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters